Trial · NCT03298984
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Alvocidib | All Participants | Bolus | 30 | mg/m2 | |
| Maximum Tolerated Dose (MTD) of Alvocidib | All Participants | IV infusion | 60 | mg/m2 | |
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib | Alvocidib 20/30 mg/m2 | 0 | Participants | ||
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib | Alvocidib 30/40 mg/m2 | 0 | Participants | ||
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib | Alvocidib 30/50 mg/m2 | 0 | Participants | ||
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib | Alvocidib 30/60 mg/m2 | 1 | Participants | ||
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 20/30 mg/m2 | Complete Remission MRD Negative (CRMRD-) | 2 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/40 mg/m2 | Complete Remission MRD Negative (CRMRD-) | 0 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/50 mg/m2 | Complete Remission MRD Negative (CRMRD-) | 2 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/60 mg/m2 | Complete Remission MRD Negative (CRMRD-) | 8 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 20/30 mg/m2 | Complete Remission MRD Positive or Unknown (CR) | 1 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/40 mg/m2 | Complete Remission MRD Positive or Unknown (CR) | 2 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/50 mg/m2 | Complete Remission MRD Positive or Unknown (CR) | 0 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/60 mg/m2 | Complete Remission MRD Positive or Unknown (CR) | 7 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 20/30 mg/m2 | Partial Remission (PR) | 0 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/40 mg/m2 | Partial Remission (PR) | 1 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/50 mg/m2 | Partial Remission (PR) | 0 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/60 mg/m2 | Partial Remission (PR) | 1 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 20/30 mg/m2 | Stable Disease | 0 | participants | |
| Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria | Alvocidib 30/40 mg/m2 | Stable Disease | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03298984/results